Abstract
Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 508-524 |
| Number of pages | 17 |
| Journal | Clinics in Dermatology |
| Volume | 36 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. / Tartar, Danielle; Chung, Lorinda; Fiorentino, David F.
In: Clinics in Dermatology, Vol. 36, No. 4, 01.07.2018, p. 508-524.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis
AU - Tartar, Danielle
AU - Chung, Lorinda
AU - Fiorentino, David F.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.
AB - Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.
UR - http://www.scopus.com/inward/record.url?scp=85049463043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049463043&partnerID=8YFLogxK
U2 - 10.1016/j.clindermatol.2018.04.008
DO - 10.1016/j.clindermatol.2018.04.008
M3 - Article
C2 - 30047434
AN - SCOPUS:85049463043
VL - 36
SP - 508
EP - 524
JO - Clinics in Dermatology
JF - Clinics in Dermatology
SN - 0738-081X
IS - 4
ER -